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Background and purpose: A growing body of evidence suggests that cardio-
vascular disease risk factors including hypertension may be linked to sporadic
Alzheimer’s disease (AD). It is well known that hypertension is associated with
cerebrovascular disease and vascular dementia on the basis of vascular remod-
eling. However, the mechanisms linking hypertension and AD remain unclear.
Methods: We studied 197 patients with AD (86 male; mean age  SD:
75.8  7.4 years) from the Alzheimer’s Disease Neuroimaging Initiative data-
base with (n = 97) and without (n = 100) hypertension. We explored associa-
tions between hypertension and clinical, plasma, cerebrospinal ﬂuid and
imaging markers of AD pathology in order to elucidate the underlying mecha-
nisms that may link AD and hypertension.
Results: We found that patients with AD with hypertension had worse cogni-
tive function (Alzheimer’s disease Assessment Scale-cognitive subscale,
P = 0.038) and higher neuropsychiatric symptom burden (Neuropsychiatric
Inventory Questionnaire, P = 0.016) compared with those without hyperten-
sion. Patients with AD with hypertension showed reduced glucose hypometa-
bolism in the right (P < 0.001) and left (P = 0.007) hippocampus. No
diﬀerences were found in magnetic resonance imaging volumetric measure-
ments, [18F]ﬂorbetapir uptakes, plasma and cerebrospinal ﬂuid between
patients with AD with and without hypertension.
Conclusions: Although hypertension is associated with worse cognitive func-
tion, behavioural symptoms and hippocampal glucose hypometabolism, it is
not associated with evidence of increased amyloid or tau pathology. Eﬀective
management of hypertension may potentially have a therapeutic role in the
alleviation of symptoms in AD.
Introduction
Alzheimer’s disease (AD) is the most common cause of
dementia, aﬀecting over 33.9 million people worldwide
[1]. The cardinal pathology in AD includes accumula-
tion of extracellular amyloid-b (Ab) plaques and intra-
cellular neuroﬁbrillary tangles of hyperphosphorylated
tau, as well as synaptic loss [2]. Over the last few years,
several large phase III clinical trials of putative disease-
modifying treatments using antiamyloid approaches
have failed [3–8]. Therefore, identifying potential modi-
ﬁable risk factors of AD is crucial for primary preven-
tion and might lead to a reduction in AD incidence.
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Several studies suggest that cardiovascular disease
risk factors, such as type two diabetes, dyslipidaemia,
metabolic syndrome and hypertension, could be linked
to sporadic AD [9–11]. Among these risk factors,
hypertension may be the most detrimental [12]. It is well
known that hypertension is the most signiﬁcant con-
tributing factor in cerebrovascular disease, as it can
cause microvascular dysfunction and narrowing, which
can lead to cerebral hypoperfusion, microhaemorrhages
and encourage cerebral small vessel disease [12]. Small
vessel disease can consequently lead to lacunar infarcts
and leukoaraiosis, changes that are closely associated
with cognitive decline and vascular dementia [12].
In contrast to the mechanisms that link hypertension
and cerebrovascular disease, the pathophysiological
links between hypertension and AD are more complex
and may involve inﬂammatory processes, blood–brain
barrier dysfunction, as well as cerebral hypoperfusion
[13–15]. Although the exact mechanisms are not fully
understood, there is strong evidence to support the
hypothesis that hypertension in mid-life leads to cogni-
tive impairment and contributes to the development of
AD in later life [16]. It is also possible that hypertension
may exacerbate AD symptoms and pathology.
Here, we investigated whether hypertension is asso-
ciated with clinical, plasma, cerebrospinal ﬂuid (CSF)
and magnetic resonance and positron emission
tomography (PET) imaging biomarkers of AD pathol-
ogy in order to elucidate the underlying mechanisms
that may link AD and hypertension.
Methods
Data used in the preparation of this article were
obtained from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database (adni.loni.usc.edu). The
ADNI was launched in 2003 as a public–private part-
nership, led by Principal Investigator Michael W.
Weiner, MD. The primary goal of ADNI has been to
test whether serial magnetic resonance imaging
(MRI), PET, other biological markers and clinical
and neuropsychological assessment can be combined
to measure the progression of mild cognitive impair-
ment and early AD. Each ADNI site received
approval from an ethical committee on human experi-
mentation before the study’s initiation. Written
informed consent for research was obtained from all
individuals participating in the study.
Study population
From theADNI I and II databases, a total of 197patients
with AD (86 male; mean age  SD: 75.8  7.4 years)
were included in the analysis (Table 1). Inclusion criteria
Table 1 Demographic characteristics, ApoE genotype and vital signs of patients with Alzheimer’s disease (AD) with and without hypertension
(HTN)
AD AD without HTN AD with HTN
No. 197 97 (49.2%) 100 (50.8%)
Gender (M) 86 (43.7%) 45 (46.4%) 41 (41.0%)
Age (years) 75.8 (7.4) 76.7 (7.2) 75.8 (7.4)
Handedness (R) 185 (98.9%) 92 (94.8%) 93 (93.0%)
Parent history of AD 23 (11.7%) 10 (10.0%) 13 (13.0%)
ANART 13.78 (8.9) 12.52 (8.6) 15.04 (9.3)
Education (years) 15.0 (3.2) 14.7 (3.3) 15.2 (3.2)
Age at onset (years) 69.6 (6.9) 69.7 (7.6) 69.5 (6.2)
Disease duration (years) 14.7 (3.2) 7.0 (8.1) 5.5 (7.1)
ApoE genotypes (no.) ApoE e2-2 = 1 ApoE e2-2 = 0 ApoE e2-2 = 1
ApoE e2-3 = 6 ApoE e2-3 = 3 ApoE e2-3 = 3
ApoE e2-4 = 2 ApoE e2-4 = 1 ApoE e2-4 = 1
ApoE e3-3 = 115 ApoE e3-3 = 49 ApoE e3-3 = 66
ApoE e3-4 = 50 ApoE e3-4 = 28 ApoE e3-4 = 22
ApoE e4-4 = 23 ApoE e4-4 = 16 ApoE e4-4 = 7
BMI 27.0 (5.8) 25.0 (4.0) 29.0 (6.7)**
SBP (mmHg) 136.7 (17.3) 131.6 (16.5) 141.6 (16.7)***
DBP (mmHg) 73.5 (9.2) 72.4 (8.5) 74.6 (9.8)
PP (mmHg) 63.2 (16.0) 59.2 (15.2) 67.0 (15.9)**
Body temperature (°C) 36.4 (0.4) 36.3 (0.5) 36.5 (0.4)
HR (bpm) 64.8 (10.4) 64.6 (10.2) 65.1 (10.4)
HMIS 0.64 (0.7) 0.65 (0.8) 0.63 (0.6)
ANART, American National Adult Reading Test; BMI, body mass index; bpm, beats/min; DBP, diastolic blood pressure; HMIS, Modiﬁed
Hachinski Ischemic Scale; HR, heart rate; M, male; PP, pulse pressure; R, right; SBP, systolic blood pressure. **P < 0.01; ***P < 0.001. Data
are given as n (%) and mean  SD.
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for all participants were: age between 55 and 90 years,
a minimum of 6 years’ education and visual/auditory
acuity adequate for neuropsychological testing. Addi-
tionally, the Modiﬁed Hachinski Ischemic Scale was
completed for all subjects using information from medi-
cal records to determine the degree of vascular involve-
ment and only subjects with a score ≤4 were included in
the study. Patients with AD fulﬁlled the National Insti-
tute of Neurological and Communicative Disorders
and Stroke and the Alzheimer’s Disease and Related
Disorders Association criteria for probable AD [17],
had a Clinical Dementia Rating (CDR) score of 0.5 or
1 and a Mini-Mental State Examination (MMSE) score
between 20 and 26. Participants had to have an MMSE
score in this range so that they could complete clinical
assessments eﬀectively.
The presence of hypertension was documented by
medical history and/or conﬁrmed by two consecutive
blood-pressure (BP) measurements. Hypertension was
categorized according to the classiﬁcation outlined in
the Seventh Report of the Joint National Committee
on Prevention, Detection, Evaluation and Treatment
of High Blood Pressure [18]. Participants with a sys-
tolic BP reading of ≥140 mmHg and/or a diastolic BP
reading of ≥90 mmHg were classed as hypertensive,
whereas subjects with a systolic BP value of
≤139 mmHg as well as a diastolic BP value of
≤89 mmHg were deemed to be normotensive. Medical
history was examined thoroughly in the database for
evidence of hypertension for each participant using
‘hypertension’ as a key word and its synonyms, such
as ‘HTN’, ‘high blood pressure’, ‘high BP’, ‘elevated
blood pressure’, ‘elevated BP’ and ‘increased blood
pressure’. Additionally, obvious spelling mistakes such
as ‘hpertension’ and ‘hyoertension’ were included.
Patients with AD were subdivided into two groups
according to the presence/absence of hypertension:
AD with hypertension (n = 97, 49.2%; 45 male) and
AD without hypertension (n = 100, 50.8%; 41 male;
Table 1). Fifty-one patients with AD (55.3%) had
both a history of hypertension and BP readings sug-
gestive of hypertension, 38 patients with AD (36.9%)
had only a history of hypertension with normal BP
readings, and the remaining eight patients with AD
(7.8%) were classiﬁed as hypertensive based only on
BP readings.
Clinical assessments
Cognitive function was assessed with the Alzheimer’s
Disease Assessment Scale-cognitive subscale (ADAS-
Cog 11) and MMSE. The ADAS-Cog 11 was not
timed and the subject’s score was not dependent on
how rapidly the test was completed. The CDR served
as a tool for quantifying the severity of symptoms of
dementia and the Modiﬁed Hachinski Ischemic Scale
was used to identify a likely vascular component once
the dementia diagnosis has been established.
Neuropsychiatric symptoms were assessed using the
Neuropsychiatric Inventory Questionnaire. Depressive
features and functional ability were assessed with the
Geriatric Depression Scale-Short Form and Func-
tional Assessment Questionnaire, respectively. The
American National Adult Reading Test was used to
assess intellectual functioning.
Plasma and cerebrospinal fluid samples
Baseline samples of plasma tau, plasma Ab40 and 42,
total plasma homocysteine, CSF total tau, CSF tau
phosphorylated at threonine 181, CSF Ab42 and CSF
alpha-synuclein were collected from participants.
ApoE genotyping was carried out on subjects using
EDTA blood samples collected during the ﬁrst visit.
Full details concerning the collection, processing and
storage procedures for plasma and CSF samples can
be found in the ADNI procedures manual (http://
www.adni-info.org/Scientists/ADNIStudyProcedures.
html). CSF samples that were thawed or contami-
nated with blood were excluded from our analysis in
order to avoid false-positive results [19]. For subjects
with two CSF samples for a single biomarker, the
highest reading was used. With respect to plasma
homocysteine analysis, samples were excluded if they
were not frozen, packed in dry ice or received within
24 h of blood draw.
Imaging procedures and analysis
Magnetic resonance imaging analysis
All participants had 1.5- or 3.0-Tesla MRI scans com-
pleted at regular intervals during the ADNI study.
Baseline T1-weighted magnetization-prepared rapid
gradient-echo (MPRAGE) images were acquired from
all participants with AD. Scans were carried out and
analysed in accordance with the ADNI MRI technical
procedures manual (http://www.adni-info.org/Scie
ntists/ADNIStudyProcedures.html). In this study,
total brain volume, brain and ventricular boundary
shift integral, and hippocampal and temporal lobe
volumes were evaluated. The boundary shift integral
was used to assess brain and ventricular volume
changes over time by determining changes in the
boundaries of the respective structure in follow-up
scans compared with the baseline scans [20].
Hippocampal volumes were analysed using a brain-
mapping tool (Medtronic Surgical Navigation Tech-
nologies, Minneapolis, MN, USA). Temporal lobe
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volume was assessed using tensor-based morphometry.
In addition to volumetric analyses, the number of visi-
ble infarcts was recorded for subjects to check for
underlying cerebrovascular disease. All images were
reviewed by a physician specially trained in the detec-
tion of MRI infarcts. Full details of the MRI proce-
dures can be found in the ADNI manual (http://
www.adni-info.org/Scientists/ADNIStudyProcedures.
html).
Positron emission tomography analysis
[18F]ﬂuorodeoxyglucose (FDG) and [18F]ﬂorbetapir
PET imaging was carried out to measure regional
rates of glucose metabolism and Ab load, respectively.
A mean dose of 5  0.5 mCi [18F]FDG (185 MBq)
was injected intravenously and data were recon-
structed using a framing rate of 5 9 300 s. Regions of
interest included the left and right temporal gyrus, left
and right angular gyrus, posterior cingulum, and left
and right hippocampus. Hippocampal metabolic activ-
ity was measured using the HipMask technique [21].
For [18F]ﬂorbetapir PET imaging, a mean dose of
10.0  1.5 mCi [18F]ﬂorbetapir (370 MBq) was
injected intravenously and data were reconstructed
using a framing rate of 4 9 300 s. Structural magnetic
resonance images were skull-stripped, segmented, par-
cellated using Freesurfer and subsequently coregis-
tered to the participants’ ﬁrst ﬂorbetapir image. [18F]
Florbetapir standardized uptake value ratios were cal-
culated using the whole cerebellum as a reference
region. Regions of interest included frontal, anterior/
posterior cingulate, lateral parietal and lateral tempo-
ral cortices. The [18F]ﬂorbetapir mean of each region
of interest was weighted by its volume to account for
the diﬀerence in sizes of the subregions. Full details of
the PET procedures can be found in the ADNI man-
ual (http://www.adni-info.org/Scientists/ADNIStud
yProcedures.html).
Statistical analysis
Statistical analyses and graphical illustrations were
performed using the Statistical Package for the Social
Sciences, version 22 (IBM Corp., Armonk, NY,
USA) and GraphPad Prism 6 (GraphPad Software,
San Diego, CA, USA), respectively. For all variables,
variance homogeneity and Gaussianity were tested
with Bartlett and Kolmogorov–Smirnov tests. Multi-
variate analysis of variance was used to assess the
main diﬀerences in clinical, CSF, plasma and imag-
ing measurements between patients with AD with
and without hypertension. If the overall multivariate
test was signiﬁcant, P values for each variable were
calculated following Benjamini–Hochberg multiple-
comparisons test in order to reduce the false discov-
ery rate. We set the false discovery rate cut-oﬀ at
0.05. All data are presented as mean  SD, and the
level a was set for all comparisons at P < 0.05, cor-
rected.
Results
Patients with AD with hypertension had signiﬁcantly
higher body mass index scores (P < 0.01), systolic BP
(P < 0.001) and pulse pressure (P < 0.01) compared
with those without hypertension. No diﬀerences were
found for age, gender, age at onset, disease duration,
years of education, American National Adult Reading
Test, family history of AD, Modiﬁed Hachinski
Ischemic Scale and ApoE genotype between patients
with AD with and without hypertension (all P > 0.10;
Table 1).
We found signiﬁcant diﬀerences in clinical mea-
surements between the patients with AD with and
without hypertension (P = 0.013). Patients with AD
with hypertension had signiﬁcantly worse cognitive
function as measured by the ADAS-Cog 11
(P = 0.038) and increased neuropsychiatric symptom
burden (P = 0.016) compared with those without
hypertension (Table 2; Fig. 1). Within the ADAS-
Cog 11, patients with AD with hypertension scored
worse on the Command item 2 (P = 0.027) and
Word Recognition item 8 (P = 0.034) compared
with patients with AD without hypertension. No
diﬀerences were found in the total CDR scores
(P > 0.10), MMSE scores (P > 0.10), Functional
Assessment Questionnaire (P = 0.088) and Geriatric
Depression Scale-Short Form (P > 0.10) between
patients with AD with and without hypertension
(Table 2).
Table 2 Clinical assessments in the group of patients with Alzhei-
mer’s disease (AD) with and without hypertension (HTN)
AD without
HTN
AD with
HTN P value* % change
CDR 0.68 (0.3) 0.73 (0.3) NS +6.4%
MMSE 24.09 (1.8) 23.94 (1.8) NS 0.6%
ADAS-Cog 11 16.58 (5.6) 18.00 (5.3) 0.038 +7.9%
GDS-SF 1.79 (1.3) 1.52 (1.4) NS 17.7%
NPI-Q 2.55 (2.5) 4.42 (3.5) 0.016 +42.3%
FAQ 10.71 (6.3) 12.69 (6.6) NS +15.6%
ADAS-Cog 11, Alzheimer’s Disease Assessment Scale-cognitive
subscale; CDR, Clinical Dementia Rating; FAQ, Functional Assess-
ment Questionnaire; GDS-SF, Geriatric Depression Scale-Short
Form; MMSE, Mini-Mental State Examination; NPI-Q, Neuropsy-
chiatric Inventory Questionnaire; NS, non-signiﬁcant. *All P values
are Benjamini–Hochberg corrected. Data are given as mean  SD.
Bold indicates signiﬁcant value (P < 0.05).
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Plasma and cerebrospinal fluid biomarkers
We found no diﬀerences in plasma tau, plasma Ab40
and 42, total plasma homocysteine, CSF total tau,
CSF tau phosphorylated at threonine 181, CSF Ab42
and CSF alpha-synuclein levels between patients with
AD with and without hypertension (all P > 0.10;
Table 3).
Imaging measurements
Magnetic resonance imaging volumetric analysis
showed no diﬀerences in total brain volume, brain
and ventricular boundary shift integral measurements,
hippocampal and temporal lobe volumes, and the
number of infarcts between patients with AD with
and without hypertension (all P > 0.10; Table 4).
Twenty-one patients with AD without hypertension
and 24 patients with AD with hypertension underwent
both [18F]FDG and [18F]ﬂorbetapir PET scans. We
found signiﬁcant decreases in [18F]FDG uptake in
patients with AD with hypertension compared with
those without hypertension (P = 0.021). Patients with
AD with hypertension had decreased [18F]FDG
uptakes in the right (P < 0.001) and left (P = 0.007)
hippocampus compared with patients with AD with-
out hypertension (Table 4; Fig. 2). No diﬀerences
were found in [18F]ﬂorbetapir standardized uptake
value ratios in any of the brain regions examined
between patients with AD with and without hyperten-
sion (all P > 0.10; Table 4).
No diﬀerences were found in cognitive assessments,
plasma and CSF biomarkers or MRI and PET mea-
surements between patients with AD with only a his-
tory of hypertension and those with both a history of
hypertension and BP readings suggestive of hyperten-
sion (all P > 0.10).
Discussion
Our study is the ﬁrst to investigate the association
between hypertension and clinical, plasma, CSF and
magnetic resonance and PET imaging biomarkers of
AD pathology. We found that hypertension in
patients with AD is associated with worse cognitive
function, increased neuropsychiatric burden and lower
hippocampal glucose metabolism.
Patients with AD with hypertension scored higher
on the ADAS-Cog 11 compared with normotensive
patients with AD. Cognitive diﬀerences between
Figure 1 Cognitive and neuropsychiatric
measurements in the groups of patients
with Alzheimer’s disease (AD) with and
without hypertension (HTN). (a) Signiﬁ-
cantly higher Alzheimer’s Disease
Assessment Scale-cognitive subscale
(ADAS-Cog 11) scores (P = 0.038) and
(b) Neuropsychiatric Inventory (NPI)
scores (P = 0.016) in patients with AD
with HTN compared with those without
HTN. *P < 0.05.
Table 3 Plasma and cerebrospinal ﬂuid (CSF) biomarkers in the group of patients with Alzheimer’s disease (AD) with and without hyperten-
sion (HTN)
AD without HTN AD with HTN P value* % change
CSF
a-SYN (ng/mL) 0.66 (0.3) 0.94 (1.1) NS +29.8%
Total tau (pg/mL) 111.61 (50.8) 116.00 (67.9) NS +3.8%
P-tau181P (pg/mL) 39.11 (20.6) 39.64 (18.1) NS +1.3%
Ab142 (pg/mL) 142.26 (45.3) 155.33 (46.3) NS +8.4%
Plasma
Homocysteine (lM) 9.70 (2.7) 11.29 (4.6) NS +14.1%
Tau (pg/mL) 3.1 (1.5) 3.1 (1.5) NS 0.0%
Ab40 (pg/mL) 153.3 (49.1) 147.9 (40.6) NS 3.6%
Ab42 (pg/mL) 36.5 (11.4) 35.6 (7.9) NS 2.5%
Ab, amyloid-b; NS, non-signiﬁcant; P-tau181P, tau phosphorylated at threonine 181; a-SYN, alpha-synuclein. *All P values are Benjamini–
Hochberg corrected. Data are given as mean  SD.
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patients with AD with and without hypertension were
also observed in speciﬁc items of the ADAS-Cog 11.
Hypertensive patients had worse results on items test-
ing word recognition and the ability to follow com-
mands. Impaired verbal learning and diﬃculties in
performing simple tasks are considered early signs of
AD [22,23], thus it is possible that hypertension might
be one of the earlier factors leading to the develop-
ment of AD. Investigating these ﬁndings in hyperten-
sive individuals without AD and in patients with mild
cognitive impairment may shed light on this intriguing
hypothesis. Previous studies have shown that hyper-
tension in healthy elderly individuals is associated
with cognitive decline and white matter lesions [24,25].
By contrast, studies examining the impact of hyper-
tension on cognitive decline in patients with AD are
limited. However, one case-control study has found
that cognitive decline is accelerated by hypertension in
patients with AD under the age of 65 years over a 6-
month period [26]. Other studies have found that both
mid-life and late-life hypertension increase the risk of
AD [9,27–29]. In both cerebrovascular disease and
AD, hypertension may irreversibly aﬀect the functions
of the ‘neurovascular unit’, a complex multicellular
functional unit involved in accomplishing the pro-
cesses of cerebral autoregulation and functional
Table 4 Magnetic resonance imaging (MRI) and positron emission tomography (PET) measurements in the group of patients with Alzheimer’s
disease (AD) with and without hypertension (HTN)
AD without HTN AD with HTN P value* % change
MRI volumetric measurements
Brain volume (mm3) 1 014 743.58 (1 173 39.0) 995 823.25 (101 268.2) NS 1.9%
BSI ventricles volume (mm3) 46.78 (21.4) 53.40 (26.3) NS +12.4%
BSI brain volume (mm3) 995.0 (108.7) 1019.9 (98.8) NS +2.4%
Hippocampus volume (mm3) 1608.65 (295.3) 1638.24 (332.5) NS +1.8%
Temporal lobe mean Jacobian (mm3) 996.43 (64.9) 988.55 (69.1) NS 0.8%
No. of infarcts 0 (0.07) 1 (0.5) NS –
[18F]FDG PET uptakes
Left hippocampus 1.00 (0.1) 0.88 (0.1) 0.007 13.6%
Right hippocampus 1.01 (0.1) 0.87 (0.1) <0.001 16.1%
Left temporal gyrus 1.10 (0.1) 1.09 (0.1) NS 0.9%
Right temporal gyrus 1.10 (0.1) 1.11 (0.1) NS 0.9%
Left angular gyrus 1.14 (0.1) 1.09 (0.2) NS 4.6%
Right angular gyrus 1.11 (0.1) 1.11 (0.1) NS 0.0%
Posterior cingulum 1.16 (0.1) 1.16 (0.1) NS 0.0%
[18F]Florbetapir SUVRs
Posterior cingulum 1.73 (0.5) 1.84 (0.4) NS +6.0%
Frontal lobe 1.56 (0.5) 1.53 (0.5) NS 2.0%
Temporal lobe 1.45 (0.5) 1.32 (0.5) NS 9.8%
Parietal lobe 1.61 (0.5) 1.58 (0.5) NS 1.9%
Insula right 1.5 (0.5) 1.30 (0.5) NS 15.4%
Insula left 1.5 (0.5) 1.33 (0.5) NS 12.8%
Temporal pole right 1.18 (0.4) 1.09 (0.3) NS 8.3%
Temporal pole left 1.20 (0.4) 1.07 (0.3) NS 12.1%
Superior temporal gyrus left 1.41 (0.5) 1.23 (0.4) NS 14.6%
Superior temporal gyrus right 1.43 (0.5) 1.30 (0.5) NS 10.0%
Parahippocampal gyrus left 1.16 (0.4) 1.07 (0.3) NS 8.4%
Parahippocampal gyrus right 1.16 (0.4) 1.07 (0.3) NS 8.4%
Hippocampus left 1.07 (0.2) 1.05 (0.2) NS 1.9%
Hippocampus right 1.05 (0.2) 1.05 (0.2) NS 0.0%
Lingual gyrus right 1.36 (0.5) 1.23 (0.4) NS 10.6%
Lingual gyrus left 1.43 (0.5) 1.30 (0.5) NS 10.0%
Precuneus right 1.77 (0.4) 1.65 (0.5) NS 7.3%
Precuneus 1.77 (0.4) 1.67 (0.5) NS 6.0%
Cuneus left 1.39 (0.5) 1.40 (0.5) NS +0.7%
Cuneus right 1.43 (0.5) 1.28 (0.4) NS 11.7%
Postcentral gyrus left 1.34 (0.5) 1.30 (0.5) NS 3.1%
Postcentral gyrus right 1.36 (0.5) 1.21 (0.4) NS 12.4%
Precentral gyrus left 1.45 (0.5) 1.35 (0.5) NS 7.4%
Precentral gyrus right 1.45 (0.5) 1.30 (0.5) NS 11.5%
BSI, boundary shift integral; FDG, ﬂuorodeoxyglucose; NS, non-signiﬁcant; SUVR, standardized uptake values ratio. *All P values are Ben-
jamini–Hochberg corrected. Data are given as mean  SD. Bold indicates signiﬁcant value (P < 0.05).
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hyperaemia [30]. Loss of autoregulation and reduced
cerebral blood ﬂow in response to regional brain
activity may cause cerebral hypoperfusion and hypox-
ia. Research has suggested that, whereas mild reduc-
tions in cerebral blood ﬂow can aﬀect protein
synthesis [13], which is essential for the synaptic plas-
ticity involved in learning and memory, chronic
hypoperfusion can increase hyperphosphorylated tau
levels in the hippocampus and cortex [14], as well as
cause progressive accumulation of Ab peptides [15]. In
addition to regulating cerebral blood ﬂow, the neu-
rovascular unit forms the basis of the blood–brain
barrier. Hypertension has been found to disrupt the
blood–brain barrier, an alteration that can lead to the
accumulation of neurotoxic molecules in the brain
such as Ab and thrombin [13].
We found that hypertensive patients with AD had
an increased neuropsychiatric symptom burden com-
pared with normotensive patients with AD. One study
has found that a history of hypertension increases the
risk of neuropsychiatric symptoms such as agitation/
aggression, anxiety and delusions in patients with AD
[31]. A more recent study in a large cohort of 457
patients with AD also showed that a history of hyper-
tension was associated with worse behavioural symp-
toms as measured by the Neuropsychiatric Inventory
Questionnaire at the time of AD diagnosis [32]. One
possible explanation for the link seen between hyper-
tension and neuropsychiatric symptoms such as delu-
sions is that there may be a reduction in cerebral
blood ﬂow in the prefrontal and temporal cortices [33].
Imaging analyses revealed decreased glucose meta-
bolism in the hippocampus of patients with AD with
hypertension. The hippocampus plays a crucial role in
memory. Reduced glucose metabolism in this region
of the brain may reﬂect underlying neuronal and
synaptic dysfunction, and could explain the greater
cognitive impairment observed in patients with AD
with hypertension compared with those without
hypertension. Glucose hypometabolism in the hip-
pocampus and temporo-parietal areas has been exten-
sively described in patients with AD [34] and mild
cognitive impairment [35,36]. Hypertension compro-
mises the integrity of blood vessel walls in the brain
leading to hypoperfusion and decreased glucose meta-
bolism, which can promote AD neuropathogenesis
[37]. Functional failure in brain microvasculature may
aﬀect the drainage of pathological misfolded proteins
[38]. It should be noted that no other regions of the
brain showed changes in glucose metabolism, perhaps
suggesting that the hippocampus is particularly vul-
nerable to changes in cerebral blood ﬂow.
Although previous studies propose that the cere-
brovascular damage could contribute to AD
(a)
(b)
Figure 2 Glucose metabolisms in the
group of patients with Alzheimer’s dis-
ease (AD) with and without hyperten-
sion (HTN). (a) Coronal summed [18F]
ﬂuorodeoxyglucose (FDG) positron
emission tomography images for: (left)
an 82.4-year-old female with a 7-year
history of AD {Mini-Mental State
Examination (MMSE), 26; Alzheimer’s
Disease Assessment Scale-cognitive sub-
scale (ADAS-Cog 11), 16.7; Neuropsy-
chiatric Inventory (NPI), 0; Functional
Assessment Questionnaire (FAQ), 5;
[18F]FDG uptakes hippocampus, left
1.09, right 1.21} and (right) a 75.8-year-
old female with an 8-year history of AD
(MMSE, 26; ADAS-Cog 11, 18.7; NPI,
8; FAQ, 21; [18F]FDG uptakes hip-
pocampus, left 0.91, right 0.88). Colour
bar reﬂects range of [18F]FDG uptake
intensity. (b) Signiﬁcantly lower [18F]
FDG uptakes in the right and left hip-
pocampus of patients with AD with
HTN compared with those without
HTN. **P < 0.01, ***P < 0.001.
[Colour ﬁgure can be viewed at wileyon-
linelibrary.com].
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pathology, we found no signiﬁcant diﬀerences in [18F]
ﬂorbetapir standardized uptake value ratios or plasma
and CSF amyloid and tau levels between patients with
AD with and without hypertension. It is possible that
the mechanisms of action of hypertension in lowering
cognitive and neuropsychiatric performance are diﬀer-
ent from those promoting AD pathology. We also
found no diﬀerences in brain and hippocampal MRI
volumetric measurements between patients with AD
with and without hypertension. Although research on
volumetric imaging changes in patients with AD with
hypertension is limited, it has been found that healthy
hypertensive individuals have signiﬁcantly larger ven-
tricular volumes and brain atrophy [39]. The fact that
we did not ﬁnd these changes in our AD population
perhaps suggests that, whereas hypertension may lead
to functional brain changes such as reduced hippocam-
pal glucose metabolism, it may have a small eﬀect on
structural volumetric brain changes for the stage of
AD studied here. We also found no diﬀerences in
ApoE genotype between patients with AD with and
without hypertension. It is known that ApoE4 is asso-
ciated with reduced lipid metabolism and vascular
function, and that high cholesterol and plaque build-
up lead to hypertension [40]. However, the allele is
associated with younger onset AD and increases AD
risk in a dose-dependent manner [30]. This may
explain why no diﬀerences were detected in our sample
of patients. Furthermore, ApoE4 is thought to have
varying modulating inﬂuence on BP [30].
There are several important limitations of this study
that need to be mentioned. In terms of methodology,
there was insuﬃcient control of antihypertensive ther-
apy and vascular comorbidities such as diabetes and
obesity. With several patients in our sample poten-
tially on BP-lowering medication, the full negative
impact of hypertension on AD symptoms and hip-
pocampal glucose metabolism is likely to be masked
and may actually be greater. Furthermore, other car-
diovascular disease risk factors may independently
inﬂuence AD pathology. Another point to note is that
the ADNI study cohort represents a clinical trial pop-
ulation. As a result, our ﬁndings may have limited
generalizability. Additionally, the ADNI study only
recruits patients with AD with a CDR score of 0.5 or
1 and an MMSE score between 20 and 26. This
means that the results obtained here are solely based
on a population of patients with early to moderate
AD. It is possible that hypertension may not have
such an impact on AD biomarkers in later stages of
the disease. The ADNI cohort also only includes sub-
jects aged 55–90 years and AD may start developing
before the age of 55 years.
In conclusion, hypertension appears to negatively
aﬀect cognitive and neuropsychiatric function and
regional brain metabolism. Our ﬁndings highlight the
urgent need to treat hypertension in a vulnerable age
group. Eﬀective management of hypertension may
potentially have a therapeutic role in the alleviation of
symptoms in AD.
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